128 related articles for article (PubMed ID: 38634742)
21. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
22. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
23. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events.
Zheng K; Qiu W; Wang H; Si X; Zhang X; Zhang L; Li X
Thorac Cancer; 2020 Jun; 11(6):1746-1751. PubMed ID: 32232975
[TBL] [Abstract][Full Text] [Related]
24. A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Xu X; Wang D; Chen W; Li N; Suwinski R; Rossi A; Rosell R; Zhong J; Fan Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4511-4525. PubMed ID: 35070757
[TBL] [Abstract][Full Text] [Related]
25. Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A; Vionnet J; Obeid M; Bouchaab H; Peters S; Latifyan S; Wicky A; Michielin O; Chtioui H; Moradpour D; Fasquelle F; Sempoux C; Fraga M
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36283734
[TBL] [Abstract][Full Text] [Related]
26. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
27. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
[TBL] [Abstract][Full Text] [Related]
28. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
Front Immunol; 2022; 13():898811. PubMed ID: 35967405
[TBL] [Abstract][Full Text] [Related]
29. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
30. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
[TBL] [Abstract][Full Text] [Related]
31. Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports.
Esposito P; Bottini A; Lecini E; Cappadona F; Piaggio M; Macciò L; Genova C; Viazzi F
Front Oncol; 2023; 13():1221135. PubMed ID: 37936605
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor-associated celiac disease.
Badran YR; Shih A; Leet D; Mooradian MJ; Coromilas A; Chen J; Kem M; Zheng H; Borowsky J; Misdraji J; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581063
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
[TBL] [Abstract][Full Text] [Related]
34. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.
Llewellyn HP; Arat S; Gao J; Wen J; Xia S; Kalabat D; Oziolor E; Virgen-Slane R; Affolter T; Ji C
J Hepatol; 2021 Nov; 75(5):1083-1095. PubMed ID: 34242700
[TBL] [Abstract][Full Text] [Related]
35. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis.
Newman JL; Stone JR
Cardiovasc Pathol; 2019; 43():107148. PubMed ID: 31518915
[TBL] [Abstract][Full Text] [Related]
37. 'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injury.
Belliere J; Sprangers B
Clin Kidney J; 2022 Oct; 15(10):1803-1806. PubMed ID: 36158160
[TBL] [Abstract][Full Text] [Related]
38. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
39. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates.
Singh S; Clemente LC; Parra ER; Tchakarov A; Yang C; Li Y; Long JP; Yee C; Lin JS
Oncoimmunology; 2022; 11(1):2124678. PubMed ID: 36185804
[TBL] [Abstract][Full Text] [Related]
40. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
